Humber Area Prescribing Committee

Date / Time 7th August 2024 13:00-15:00

Venue MS Teams

Chair Dr Sergio Raise

Notes / Action Points Luke Storr – Senior Pharmacy Technician, HUTH

Quorate: Yes / NoNo – JM contacted NP/AM/JG outside meeting and confirmed approved documentation.

Attendance Dr Sergio Raise, ERY sub-locality GP Prescribing Lead (SR)

Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)

Luke Storr – Senior Pharmacy Technician, HUTH (LS)

Andrew Karvot - Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)

Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)

Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)

Marian Opoku-Fofie - Deputy Chief Pharmacist - Humber Teaching NHS Foundation Trust (MOF)

Simon Priestley- Chief Pharmacist, NLAG (SP)

Natasha Suffill- Lead Clinical Pharmacist CHCP (NS)

Dr Pratik Basu- GP- The Birches medical practice (PB)

Jeeten Raghwani - GP- Greenlands Surgery (JR)

Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS (CS)

Apologies Daniel Newsome- Principal Pharmacist RDTC (DN) – PR sent in place

Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB

(LA)

Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)

Joanne Goode - Chief Pharmacist - HUTH (JG)

Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)

Dr Narayana Pothina- Consultant in adult medicine, NLAG (NP)

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.08.01	Apologies	Noted above			
2024.08.02	Declarations of interest	Nil			
2024.08.03	Minutes of previous meeting	Accepted as true record			
2024.08.04	Action Tracker	Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) JM to provide RS information on number of patients in NEL/NL December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL). March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update April update: Riluzole to JM to update websites to include NL May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group September 2023 update: For September guideline group October 2023 update: For November Guideline group December 2023 update: For November Guideline group December 2023 update: For January or March guideline group Lot check against York mycophenolate.	Action complete	JM/RS/CS	8/24

Ephruary 2024 undate: reviewed against Verk SCE and			
February 2024 update: reviewed against York SCF and contacted neuromuscular lead with national SCF. For March			
guideline group			
April 2024 update: RDTC have published reviewed and updated			
SCF. Neuromuscular lead happy with to update but to do as			
immunosuppression SCF for all places and specialities that use			
May 2024 update: SCF update ongoing			
June 2024 update: SCF update mycophenolate to be removed from here (update to include all indications for MMF) however			
funding for modafinil not yet resolved.			
July 2024 update: Modafanil funding for NL ongoing			
August 2024 update: to close action and to address funding with			
the shared care enhanced service/ near patient testing			
enhanced service work.			
	Ongoing	JM	10/24
Outstanding actions from HERPC Renal repatriation:	Ongoing	JIVI	10/24
November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To			
update further next time.			
December update – Not met with renal yet.			
March update – Updating business case.			
May update – to meet with NHSE			
August update – to meet with NHSE			
September update: not yet met with NHSE			
October update: not yet met with NHSE			
November update: not yet met with NHSE			
December update: meeting arranged with NHSE			
· · · · · · · · · · · · · · · · · · ·			
February update: meeting arranged and business case in			
progress April 2024 update: JM and LA met with Paul McManus to			
discuss further.			
May 2024 update: business case ongoing			
July 2024 update: ongoing	Action complete	JM	8/24
Blueteq Non compliance to NICE guidance in acute trusts and financial	Action complete	JIVI	0/24
Non-compliance to NICE guidance in acute trusts and financial			
impact			
June update: JM to submit ustekinumab report in			
gastroenterology HUTH when approved			
JM to present infliximab maintenance and initiation audits in			
gastroenterology HUTH when completed and approved			
July update: JM to update next time.			

August update: no further update, infliximab audit in HUTH started September update: HUTH audits still ongoing October update: HUTH audits still ongoing November update: HUTH audits still ongoing December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch. February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance. March 2024 update: Infliximab paper due to presented at April D&TC April 2024 update: HUTH D&TC not until next week to update next time May 2024 update: Infliximab paper presented to HUTH D&TC at last meeting alongside updated guidance (on agenda). HUTH infliximab IBD audit was presented to D&TC and noted multiple dosage regimens are in use. Evaluated cost effectiveness versus current second line agents (vedolizumab or ustekinumab) and escalated infliximab is significantly more cost effective. This will be reviewed as more biosimilar agents become available. July 2024 update: for further discussion at HUTH D&TC as compliance with NICE guidance for red drugs is an internal acute trust issue. August 2024 update: to close here. To add joint Humber Partnership Medicines and Therapeutics meeting agenda. Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper. September update: September D&TC next week, further updates to pathway needed October update: Awaiting updated pathway	Ongoing	JM	10/24

	November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch. December update: ongoing February 2024 update: JG to follow up with Dr Ogumbambi March 2024 update: JG raised at HUTH D&TC to bring NLAG RA pathway to next guideline group and invite Dr Alvi. April 2024 update: NLAG RA pathway on agenda May 2024 update: HUTH RA pathway currently circulating rheumatologists for comment. July 2024 update: HUTH RA pathway updates in progress following comments			
	August 2024 update: updates completed and send back around			
	rheumatologists Ratification of guidelines and SCFs: Amiodarone SCF	Action complete	JM	10/24
	JM to do minor updates and feedback to cardiology team at	Action complete	JIVI	10/24
	HUTH; check patient number for NEL/NL from NLAG/HUTH			
	September 2023 update: JM fed back to cardiology team and			
	updated. JM/AK to confirm patient numbers being dispensed at NLAG sites.			
	October 2023 – RS fed back comments from NEL/NL GP leads.			
	JM sent comments to cardiology team. JM confirmed patient			
	numbers from outsourced outpatients at NLAG.			
	November 2023 – to be discussed at next cardiology			
	governance			
	December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review			
	February 2024 update: ongoing			
	March 2024 update: JM to send updated SCF to CS for review.			
	April 2024 update: ongoing			
	May 2024: reviewed and needs reviewing against RDTC			
	documentation. Either back to guideline/SCF group or to APC			
	dependant on number of changes. July 2024: on agenda for next guideline group			
	August 2024: on agenda for flext guideline group August 2024: on agenda, action complete			
	Feedback from Integrated Medicines Optimisation	Ongoing	JM/KMc	8/24
	Committee			
	Sodium valproate prevent compliance			
	December 2023 –RS sent JM audit report and JM fed back to			
	neurologists who state all their patients have annual review and forms.			
	ioiiiis.			

		March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. June 2024 update – updated SCF on agenda July 2024 update – updated SCF on agenda August 2024 update – Comments from last meeting sent to CS, final version to be circulated when ready. Ratification of guidelines and SCFs To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance April 2024 update: ongoing	Ongoing	JM	4/24
		May 2024: ongoing July 2024: ongoing Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded April 2024 update: ongoing	Ongoing	JM	4/24
		May 2024: ongoing July 2024: ongoing Ratification of joint formulary Update joint formulary with chapter 3 Ratification of joint formulary	Ongoing	JM/LS/AK	9/24
		Update joint formulary with chapter 11 Traffic Light Status	Ongoing	JM/LS/AK	9/24
		To update formulary (netformulary) – action complete Traffic Light Status	Action complete	JM/LS/AK	8/24
		To update formulary (HERPC) - action complete Traffic Light Status	Action complete	JM/LS/AK	8/24
		To update red list (HERPC) - action complete RDTC updates To update petFormular with NICE TAG	Action complete	JM/LS/AK	8/24
		To update netFormulary with NICE TAS Any other business Add citaglistic to ignt formulary agends	Action complete	AK/JM	9/24
2024.08.05	Traffic Light Status	Add sitagliptin to joint formulary agenda. RSV vaccines- approved	Action complete To update formulary	LS JM/LS/AK	8/24 7/24
2024.08.06	Feedback from Integrated Medicines Optimisation	Atogepant- as funding movement needs approval at each of the placed.	Noted	22377.11	.,
	Committee	 Blood glucose monitoring- approved Edoxaban and anticoagulants- work on making sure weights are up to date 	Noted		

		Topiramate MHRA drug safety update discussed.			
2024.08.07	Work plans	a) Joint formulary alignmentb) Shared care frameworksc) Guidelines	Ongoing for information only		
2024.08.08	Ratification of joint formulary	Nil this month			
2024.08.09	Ratification of guidelines and SCFs	 a) Amiodarone SCF – amendments following comments from NEL/NL places. Not in enhanced services in NEL/NL; this to be addressed within current enhanced services discussions. b) Migraine (Amber guidance) – updated with information on topiramate safety, atogepant and chronic migraine pathway updated. To check links as stated a number not working and cannot be uploaded until atogepant funding resolved. Content approved. c) Prasugrel (Amber guidance) – reviewed guidance from HERPC guidance, updated onto new template. Addition of information on gastroprotection. d) Sublingual immunotherapy – reclassification changes reviewed however needs considering at NY&Y APC as well. Funding would need reviewing as well. Guideline content approved however cannot be uploaded until discussed at NY&Y APC. JM to send documentation to NY&Y APC for review and comment. e) Ticagrelor 90mg – reviewed guidance from HERPC guidance, updated onto new template. Addition of information on gastroprotection. f) Iron deficiency pathway – extensive discussions on pathway, committee felt pathway needed more clarification prior to coming back to APC. g) Lipid guideline – reviewed guidance which has been updated with classification of bempedoic acid and new target ranges. The familial hypercholesterolaemia is currently undergoing updates and when completed will be added into the document (the current version will be linked in). 	a) Approved, to upload b) To check links and upload when atogepant funding resolved c) Approved, to upload d) Approved e) Deferred- more work required f) Approved, to upload	JM	
2024.08.10	RDTC updates	• June 2024	Update formulary/red list	JM/LS/AK	
2024.08.11	Minutes from subcommittees	a) Joint formulary subcommittee (Nil) b) Guideline subcommittee (Nil)	Attached for info only		

2024.08.12	Additional minutes for information	a) HUTH D&TC (Nil) b) HFT DTG (May 24) c) NLAG M&T (June 24) d) NYY APC (June 24)	Attached for info only	
2024.08.13	Correspondence received	Nil this month		
2024.08.14	AOB			
2024.08.15	Date of next meeting	4 th September 2024 13.00 – 15.00 Teams		